Eton Pharmaceuticals, Inc.
ETON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710340
In the last 90 days, Eton Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $722.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Eton Pharmaceuticals, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 45
- +1 vs. Q1 2024
- Shares held
- 8.72M
- +1.05M (+13.6%) vs. Q1 2024
- Total value
- $28.7M
- −$91.4K (−0.3%) vs. Q1 2024
- New holders
- 7
- 6 more added
- Sold out
- 6
- 16 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ETON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 164 | $722.6M |
| Q1 2026 | 116 | $438.6M |
| Q4 2025 | 104 | $277.5M |
| Q3 2025 | 103 | $394.7M |
| Q2 2025 | 87 | $243.3M |
| Q1 2025 | 86 | $189.7M |
| Q4 2024 | 71 | $181.5M |
| Q3 2024 | 48 | $60.0M |
| Q2 2024 | 45 | $28.7M |
| Q1 2024 | 44 | $28.8M |
| Q4 2023 | 56 | $33.5M |
| Q3 2023 | 50 | $28.8M |
| Q2 2023 | 33 | $20.9M |
| Q1 2023 | 35 | $22.5M |
| Q4 2022 | 31 | $18.2M |
| Q3 2022 | 32 | $14.4M |
| Q2 2022 | 29 | $14.6M |
| Q1 2022 | 31 | $27.4M |
| Q4 2021 | 32 | $24.1M |
| Q3 2021 | 37 | $29.5M |
| Q2 2021 | 46 | $48.1M |
| Q1 2021 | 50 | $63.7M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Eton Pharmaceuticals, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 2,395,000 | $7.88M | 1.80% | −50,781−2.1% | Reduced |
| Vanguard Group Inc | 1,027,688 | $3.38M | 0.00% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 940,733 | $3.10M | 0.31% | +940,733 | New |
| Westside Investment Management, Inc. | 585,400 | $1.93M | 0.44% | +11,440+2.0% | Added |
| Acuitas Investments, LLC | 579,960 | $1.91M | 1.02% | 00.0% | Unchanged |
| National Philanthropic Trust | 492,112 | $1.62M | 0.03% | 00.0% | Unchanged |
| Paradigm Capital Management Inc | 300,000 | $987.0K | 0.04% | 00.0% | Unchanged |
| BlackRock Inc. | 282,389 | $929.1K | 0.00% | −563−0.2% | Reduced |
| Bridgeway Capital Management, LLC | 253,362 | $833.6K | 0.02% | 00.0% | Unchanged |
| Parkman Healthcare Partners LLC | 253,197 | $833.0K | 0.11% | +54,029+27.1% | Added |
| Geode Capital Management, LLC | 240,331 | $790.9K | 0.00% | +6,164+2.6% | Added |
| Aristides Capital LLC | 200,000 | $658.0K | 0.27% | +200,000 | New |
| Susquehanna International Group, LLP | 134,288 | $441.8K | 0.00% | −64,931−32.6% | Reduced |
| Thompson Siegel & Walmsley LLC | 127,724 | $420.0K | 0.01% | +127,724 | New |
| Acadian Asset Management LLC | 120,574 | $395.0K | 0.00% | −35,812−22.9% | Reduced |
| Stonepine Capital Management, LLC | 110,000 | $361.9K | 0.33% | +110,000 | New |
| Renaissance Technologies LLC | 106,500 | $350.4K | 0.00% | +41,469+63.8% | Added |
| State Street Corp | 81,403 | $267.8K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 74,491 | $245.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 59,849 | $196.9K | 0.00% | −1,281−2.1% | Reduced |
| Goldman Sachs Group Inc | 57,503 | $189.2K | 0.00% | −61,352−51.6% | Reduced |
| Schonfeld Strategic Advisors LLC | 50,917 | $167.5K | 0.00% | −45,952−47.4% | Reduced |
| Squarepoint Ops LLC | 41,255 | $135.7K | 0.00% | −7,838−16.0% | Reduced |
| Connor, Clark & Lunn Investment Management Ltd. | 34,847 | $114.6K | 0.00% | −4,450−11.3% | Reduced |
| Blair William & Co | 34,500 | $113.5K | 0.00% | −2,479−6.7% | Reduced |
| Essex Investment Management Co LLC | 27,252 | $89.7K | 0.02% | −51,361−65.3% | Reduced |
| Chicago Trust Co NA | 16,700 | $54.9K | 0.01% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 16,485 | $54.2K | 0.00% | −15,305−48.1% | Reduced |
| Charles Schwab Investment Management Inc | 13,239 | $43.6K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 11,739 | $38.6K | 0.00% | −2,364−16.8% | Reduced |
| Quantum Private Wealth, LLC | 11,500 | $37.8K | 0.01% | 00.0% | Unchanged |
| UBS Group AG | 11,018 | $36.2K | 0.00% | +9,058+462.1% | Added |
| Dimensional Fund Advisors LP | 10,564 | $34.8K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 10,250 | $33.7K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,638 | $12.0K | 0.00% | −3,955−52.1% | Reduced |
| ADAR1 Capital Management, LLC | 1,200 | $3.95K | 0.00% | +1,200 | New |
| Plante Moran Financial Advisors, LLC | 1,000 | $3.29K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 747 | $2.00K | 0.00% | −18−2.4% | Reduced |
| BNP Paribas Arbitrage, SA | 350 | $1.15K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 300 | $987 | 0.00% | +300 | New |
| Morgan Stanley | 192 | $632 | 0.00% | +154+405.3% | Added |
| Bank of America Corp | 183 | $602 | 0.00% | +183 | New |
| Citadel Advisors LLC | 32 | $105 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 4 | $14 | 0.00% | −44,610−100.0% | Reduced |
| Lindbrook Capital, LLC | 4 | $13 | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −23,078−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −19,155−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −17,700−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −1,848−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1,425−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −576−100.0% | Sold out |